z-logo
open-access-imgOpen Access
AAV-Mediated Lysophosphatidylcholine Acyltransferase 1 (Lpcat1) Gene Replacement Therapy Rescues Retinal Degeneration inrd11Mice
Author(s) -
Xufeng Dai,
Juanjuan Han,
Yan Qi,
Hua Zhang,
Lue Xiang,
JiNeng Lv,
Jie Li,
WenTao Deng,
Bo Chang,
William W. Hauswirth,
Jijing Pang
Publication year - 2014
Publication title -
investigative ophthalmology and visual science
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.935
H-Index - 218
eISSN - 1552-5783
pISSN - 0146-0404
DOI - 10.1167/iovs.13-13654
Subject(s) - retinal degeneration , erg , retinal , biology , electroretinography , outer nuclear layer , retina , scotopic vision , opsin , genetic enhancement , microbiology and biotechnology , rhodopsin , gene , neuroscience , genetics , biochemistry
The retinal degeneration 11 (rd11) mouse is a newly discovered, naturally occurring animal model with early photoreceptor dysfunction and rapid rod photoreceptor degeneration followed by cone degeneration. The rd11 mice carry a spontaneous mutation in the lysophosphatidylcholine acyltransferase 1 (Lpcat1) gene. Here, we evaluate whether gene replacement therapy using the fast-acting tyrosine-capsid mutant AAV8 (Y733F) can arrest retinal degeneration and restore retinal function in this model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom